Mass cytometry papers in (solid) cancers from 2020

You will find the list of papers of mass cytometry (CyTOF) in solid cancer in 2020.

It might help you to see the work already done in the field this year.

 

We added the material analysed and the number of markers in the mass cytometry panel used so you can get inspired. We also mentioned the journal the article is published in. 

A short description of the findings from mass cytometry is added for better clarity. This can be the start of a review on high dimensional profile findings in solid cancer for example.

For blood cancers, you can visit our special page, treating about mass cytometry in blood cancerWe started to list COVID19-related mass cytometry studies as well. 

11- Jan -2021

Yukie Kashima

Materials

15 + 5 patients

Number of markers

30 markers

Comparison between profiling of CyTOF and sc-RNA-seq of tumors and blood (fresh and frozen) from colorectal and gastric cancer patients.

Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens

Scientific Reports

5-Jan-2021

Luciano Galdieri

Materials

6 patients

Number of markers

20 markers

Immune investigation of glioblastoma stem cells by mass cytometry. 15 distinct populations among the glioblastoma stem cells.

Defining phenotypic and functional heterogeneity of glioblastoma stem cells by mass cytometry

JCI Insights

8-Dec-2020

Ivana Peran

Materials

Mouse model

Number of markers

Not available

Investigation of disruption between CAF and pancreatic cancer cells by using KO model.

Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice

Gastroenterology

4-Dec-2020

Melissa A. Galati

Materials

Organs from Pole mutated mice

Number of markers

30 markers

Mouse models investigating the role of POLE, since POLE mutations are a major cause of hypermutant cancers.

Cancers from Novel Pole-Mutant Mouse Models Provide Insights into Polymerase-Mediated Hypermutagenesis and Immune Checkpoint Blockade

Cancer Research

26-Nov-2020

Xiaoliang Huang

Materials

6 patients

Number of markers

9 markers

UBC9 is the sole conjugating enzyme in sumoylation and plays a pivotal role in homeostasis and restraining stress reactions. Here, the authors used CyTOF to explore association between bladder cancer stem cell-like population and UBC9 expression.

UBC9 coordinates inflammation affecting development of bladder cancer

Nature

16-Nov-2020

Anastasia Prokopi

Materials

Transgenic mice

Number of markers

Not shown

Immune characterizaton in tumor and tumor-draining lymph nodes (LNs) on DCs and T cells.

Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy

Journal for ImmunoTherapy of Cancer

26-Oct-2020

Nina G. Steele

Materials

Number of markers

CyTOF and sc-RNA-seq of PDAC. Highlight TIGIT as a marker upregulated on CD8+ T cells.

Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer

Nature Cancer

30-Oct-2020

Zhixuan Li

Materials

15 patients

Number of markers

35 markers

Proportion and study of CD8+PD1+CD161+ cells among tumor tissues and adjancent normal tissues.

The identification and functional analysis of CD8+PD-1+CD161+ T cells in hepatocellular carcinoma

Nature Precision Oncology

20-Oct-2020

Erika J Crosby

Materials

28 patients

Number of markers

30 markers

Investigation of vaccination with
alphaviral replicon particles encoding tumor associated
antigens to check if this would generate clinically significant antitumor
immunity to enable prolonged overall survival. Checked by mass cytometry with a decrease of Treg.

Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio

Journal for ImmunoTherapy of Cancer

30-Sept-2020

Marit van Elsas

Materials

6 different mouse models

Number of markers

24 markers

Role of neutrophils in 6 different mouse tumor models by injection of antimicrobial peptides

Host genetics and tumor environment determine the functional impact of neutrophils in mouse tumor models

JITC

21-Sept-2020

Meliha Mehmeti-Ajradini

Materials

PBMC from 2 healthy donors, 2 patients with breast cancer, 2 malignant melanoma, 1 Gram+ sepsis

Number of markers

27 markers

Function of human granulocytic G-MDSC subset during tumor progression. G-MSDC derived from cancer patients has an unique immature neutrophil profile, closer from donor than from sepsis patients.

Human G-MDSCs are neutrophils at distinct maturation stages promoting tumor growth in breast cancer

Life Science

17-Sept-2020

Theresa Proia

Materials

Mice (4 ≠ models) + 12 patients (blood + tissues, D0 and week 4)

Number of markers

Not accessible yet

Investigation of Danvatirsen, targeting STAT3 in mice and in human. STAT3 treatment reverses a suppressive TME and promotes pro-inflammatory gene expression changes in patients' tumors and mouse models.

STAT3 antisense oligonucleotide remodels the suppressive tumor microenvironment to enhance immune activation in combination with anti-PD-L1

Clinical Cancer Research

10-Sept-2020

Theresa Proia

Materials

CT26 mice (Ctrl, anti-PD-L1, STAT3, Combination)

Number of markers

40 markers

Study of Danvartisen, an anti-STAT3 by mass and flow cytometry, immunofluorescence analysis of CT26.

STAT3 antisense oligonucleotide remodels the suppressive tumor microenvironment to enhance immune activation in combination with anti-PD-L1

Clinical Research Cancer

09-Sept-2020

Yannick Simoni

Materials

1 patient (tumor + blood)

Number of markers

22 markers (excl. tetramers)

Study case of one patient suffering from lymphoepithelioma‐like carcinoma. Invetigation on the antigen specificity and phenotype of EBV-specific CD8+ T cells in blood and lung tumor.

Partial absence of PD‐1 expression by tumor‐infiltrating EBV‐specific CD8+ T cells in EBV‐driven lymphoepithelioma‐like carcinoma

Clinical & Translational Immunology

06-Sept-2020

Ahmed Omar Kaseb

Materials

1 patient

Number of markers

36 markers

Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma

Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma

Cancer Immunology Research

06-Sept-2020

Di Zhao

Materials

Pten and Pten/Smad4 genetically engineered mouse models

Number of markers

Not given

Role of CHD1 in PTEN-deficient prostate cancer. Chd1 deletion was associated with profound tumor microenvironment (TME) remodeling characterized by reduced myeloid-derived suppressor cells (MDSC) and increased CD8+ T cells.

Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer

Cancer Discovery

31-Aug-2020

Megan T. Hoffman

Materials

7 mice Gnat3-/-

Number of markers

16 markers

Description of the immunomodulatory role of chemosensory signaling in metaplastic tuft cells (MTCs) by analyzing the role of GNAT3, a gustatory pathway G-protein expressed by MTCs, during Pancreatic Ductal Adenocarcinoma progression

The Gustatory Sensory G-Protein GNAT3 Suppresses Pancreatic Cancer Progression in Mice

CMGH

31-Aug-2020

Felix J. Hartmann

Materials

20 healthy & 8 colon carcinoma

Number of markers

46 + 43 (≠ panels tissues/ blood)

Investigating metabolism together with phenotype: new method single-cell metabolic regulome profiling (scMEP). Can also be combined with spatial organization MIBI-TOF.

Single-cell metabolic profiling of human cytotoxic T cells

Nature Biotechnology

28-Aug-2020

Yu Zhang

Materials

KPC model (pancreatic cancer in mouse)

Number of markers

31 markers

Role of IL-17 in pancreatic cancer. IL17 recruits neutrophils, triggers neutrophil extracellular traps (NETs), and excludes cytotoxic CD8 T cells from tumors. Additionally, IL17 blockade increases immune checkpoint blockade (PD-1, CTLA4) sensitivity. Clinical studies with IL17 and checkpoint blockade represent a novel combinatorial therapy with potential efficacy for this lethal disease.

Interleukin-17–induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer

JEM

26-Aug-2020

Megan T. Hoffman

Materials

Gnat3 deficient mice

Number of markers

16 markers

Investigation of a specific protein called Gnat3 in pancreatic cancer, modelized in mouse. Ablation of Gnat3 in KC organoids increased release of tumor-promoting cytokines in
conditioned media, including CXCL1 and CXCL2. This leads to an alteration of the MDSC population and promotion of metastatic PDAC.

The Gustatory Sensory G-Protein GNAT3 Suppresses Pancreatic Cancer
Progression in Mice

Cellular and Molecular Gastroenterology and Hepatology

20-Aug-2020

Sabine Mueller

Materials

28 patients

Number of markers

26 markers

Immune investigation of the vaccine H3.3K27M in diffuse midline glioma. Patients with below-median baseline levels of myeloid-derived suppressor cells had prolonged OS compared to their counterparts. Immediate pre-treatment dexamethasone administration inversely associated with H3.3K27M-reactive CD8+ T-cell responses.

Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma

JCI

18-Aug-20

Annie A. Wu

Materials

20 patients from Arm A PBMC at baseliune and week 7.

Number of markers

32 markers

Comparison of GVAX + ipilimumab (Arm A) versus FOLFIRINOX (Arm B) in metastatic pancreatic cancer. Mass study focused on difference between baseline and week 7 in Arm A.

A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer

Clinical Cancer Research

19-Aug-2020

Natsuko Kondo

Materials

Mouse

Number of markers

25 markers

Investigate the Boron Neutron Capture Therapy in glioblastoma to check if P-boronophenylalanine is taken up by glioma stem-like cells and study their phenotype.

Glioma Stem-Like Cells Can Be Targeted in Boron Neutron Capture Therapy with Boronophenylalanine

Cancers

13-Aug-2020

Di Zhao

Materials

11 mice

Number of markers

6 markers

Mass cytometry performed on Ptenpc−/− (n = 6 mice) and
Pten/Chd1pc−/− (n = 5 mice) tumors

Chromatin Regulator, CHD1, Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer

Cancer Discovery

07-Aug-2020

Julie N. Graff

Materials

10 patients PBMC of prostate cancer

Number of markers

19 markers

Efficacy of the CTLA-4 targeted agent, ipilimumab, in metastatic prostate cancer patient. Mass cytometry of PBMC showed an increase of effector Th1 subsets.

Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy

Frontiers in Oncology

06-Aug-2020

Elham Beyranvand Nejad

Materials

TC-1 mouse tumor model

Number of markers

37 markers

Relapse mechanisms of immunotherapy by studying TC-1 model.

Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapy

JITC

06-Aug-2020

Jasneet Kaur Khalsa

Materials

Diverse mouse GBM lines

Number of markers

31 markers

Study of glioblastoma in mice by combining 3 techniques: RNA-sequencing, CyTOF and correlative immunohistochemistry. Identification of immunologically-inert (exhausted CD8 T cells and resident macrophages, fewer eosinophils and SiglecF+ macrophages) and -active syngeneic-tumor types.

Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types

Nature Communications

21-July-2020

Avanish Mishra

Materials

2 leukapheresis samples from healthy donors via negative depletion

Number of markers

20 markers

Isolation of circulating tumor cells in cancer patients by creating an ultrahigh-throughput magnetic sorter. Non

Ultrahigh-throughput magnetic sorting of large blood volumes for epitope-agnostic isolation of circulating tumor cells

PNAS

16-Jul-2020

Bo Zheng

Materials

39 matched hepatocellulalr carcinoma, nontumor, and leading-edge tissue

Number of markers

35 markers

Tumor-associated double positive CD4 and CD8 cells are enriched in leading edge regions with synergetic expression of PD-1/HLA-DR/ICOS/CD45RO, indicating favorable prognosis.

Trajectory and Functional Analysis of PD1 high CD4+ CD8+ T Cells in Hepatocellular Carcinoma by Single-Cell Cytometry and Transcriptome Sequencing

Advanced Science News

18-July-2020

Qinchen Lu

Materials

30 HCC

Number of markers

29 markers

single-cell mass cytometry and fluorescence-activated cell sorter were applied to evaluate the potential association between the expression of lncRNA and the stemness of HCC

Integrated RNA Sequencing and Single-Cell Mass Cytometry Reveal a Novel Role of LncRNA HOXA-AS2 in Tumorigenesis and Stemness of Hepatocellular Carcinoma

Dovepress

08-Jul-20

Charles P. Couturier

Materials

whole-tumor cells, progenitor cancer cells, and non-progenitor cells

Number of markers

39 markers

Cell cycle analysis by mass cytometry analysis. Mass cytometry showed that progenitor cancer cells are the main cycling cell population in the tumor.

Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy

Nature Communications

07-Jul-20

Lynn Jeanette Savic

Materials

3 groups of rabbits,

Number of markers

1 marker

Tumor model was used to visualize resistance mechanisms mediated by the immuno-metabolic interplay that inform response to immunotherapies

Molecular MRI of the Immuno-Metabolic Interplay in a Rabbit Liver Tumor Model: A Biomarker for Resistance Mechanisms in Tumor-targeted Therapy?

Radiology

30-June-20

M Hope Robinson

Materials

9 low grade glioma patients + 1 high grade glioma patient

Number of markers

36 markers

Evaluation of T-cells infiltrating
pediatric glial tumors. Low-grade tumors
are characterized by greater T-cell density compared
with high-grade glioma (HGG). T-cells within both HGG and
low-grade glioma (LGG) exhibit phenotypic heterogeneity
and tissue-resident memory T-cells consist of distinct
subsets of CD103+ and TCF1+ cells that exhibit distinct
spatial localization patterns. TCF1+ T-cells are located
closer to the vessels while CD103+ residentT-cells reside
within the tumor further away from the vasculature.

Subtype and grade-dependent spatial
heterogeneity of T-cell infiltration in
pediatric glioma

JITC

25-Jun-20

Ekaterina Friebel

Materials

38 patients with primary brain tumors or brain
metastases

Number of markers

Myeloid panel: 39/ Lymphoid: 44 markers

T-cell engaging CD3 bispecific testing: PF-07062119 showed potent T-cell mediated in vitro activity and in vivo efficacy in multiple CRC human xenograft tumor models

Single-Cell Mapping of Human Brain Cancer Reveals
Tumor-Specific Instruction of Tissue-Invading
Leukocytes

Cell

23-Jun-20

Andrew L. Ji

Materials

10 human skin SCCs and matched normals via scRNA-seq, ST, and MIBI

Number of markers

37 markers

Characterization of human cutaneous squamous cell carcinoma: mass cytometry identifies a tumor-specific keratinocyte population and immune infiltrates and heterogeneity at tumor
leading edges

Multimodal Analysis of Composition and Spatial
Architecture in Human Squamous Cell Carcinoma

Cell

23-06-2020

Materials

24 CRC 11 NSCLC 9 RCC

Number of markers

39 markers

Comprehensive profiling of tumor-infiltrating MAIT cells in colorectal cancer (CRC)

Human Tumor-Infiltrating MAIT Cells Display Hallmarks of Bacterial Antigen Recognition in Colorectal Cancer

Cell Reports Medicine

23-Jun-20

Nalin Leelatian

Materials

28 glioblastoma patients

Number of markers

34 markers

Novel computational tool, RAPID, to identify cell type clusters that inform on patient survival. Mass cytometry stratified patients according to their overall survival. Patient can be classified into negative and positive prognostic using S100B and EGFR protein abundance

Unsupervised machine learning reveals risk stratifying glioblastoma tumor cells

eLife

16-Jun-20

Eva Castellano

Materials

44 samples obtained at different time points of the treatment from 12 different BCG-treated bladder cancer patients.

Number of markers

40 markers

Novel population of CD15+CD66b+CD14+ CD16+ cells was very abundant in several samples. Samples of patients with a stronger inflammatory response contained more cells in urine

CyTOF analysis identifies unusual immune cells in urine of BCG-treated bladder cancer patients

bioRXiv

05-Jun-20

Jinheng Wang

Materials

4T1-tumor mice model

Number of markers

11 markers

Mass cytometry comprehensively reveals the fate of exosomes at the single-cell level

High-throughput single-cell analysis of exosome mediated dual drug delivery, in vivo fate and synergistic tumor therapy

Nanoscale

08-Jun-20

Kevin L.M. Chua

Materials

10 patients with metastatic disease, who had responded to anti-PD-1/ anti-PD-L1 ICB and
received radiotherapy at Baseline (pre-RT), 1-2 weeks post-RT and post-ICB#1

Number of markers

40 marker-panel

Systemic immune reaction to RadioTherapy (RT)-Immune Checkpoint Blockade (ICB): Ki-67+ CD8+ T cells were increased post-RT and further expanded upon re-introduction of ICB post-RT

High-dimensional Characterization of the Systemic Immune Landscape Informs on Synergism between Radiotherapy and Immune Checkpoint Blockade

International Journal of Radiation

02-Jun-20

Anders Handrup Kverneland

Materials

6 patients with late-stage metastatic high-grade serous OC were treated with immune therapy consisting of ipilimumab followed by surgery to obtain TILs and infusion of REP-TILs

Number of markers

36 markers

Mass-cytometry shows primarily activated and differentiated effector memory T cells. REP-TILs (low-dose IL-2 and nivolumab)showed in vitro reactivity and expression of inhibitory receptors, such as LAG-3 and PD-1. Addition of ipilimumab therapy improves T cell fold expansion during production, increase level of CD8 T cell tumor reactivity, and favorably affects the T cell phenotype.

Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer

Oncotarget

28-May-20

Davis Y. Torrejon

Materials

Mice: MC38 (colon carcinoma) wild-typ, JAK1/2 and B2M knockout tumors

Number of markers

30 markers

Investigation of PD-1 resistant tumors through JAK1/JAK2 and B2M genetically modified models.

Overcoming Genetically Based Resistance
Mechanisms to PD-1 Blockade

Cancer Discovery

25-May-20

Breanna M. Allen

Materials

Different mouse tumor models

Number of markers

41 markers

Systemic immune changes were reversed with surgical tumor resection, and many were prevented by interleukin-1 or granulocyte colony-stimulating factor blockade, revealing remarkable plasticity in the systemic immune state.

Systemic dysfunction and plasticity of the immune macroenvironment in cancer models

Nature Medicine

07-May-20

Weilun Fu

Materials

3 initial and 3 recurrent GBM samples and their matched peripheral blood mononuclear cells (pPBMCs).

Number of markers

30 markers

Exhausted T cell and regulatory T cell percentages were significantly higher in tumors than in PBMCs. NK cells that infiltrated into the tumor lesions expressed higher levels of CXCR3, as these cells expressed lower levels of IFNγ

Single-Cell Atlas Reveals Complexity of the Immunosuppressive Microenvironment of Initial and Recurrent Glioblastoma"

Frontiers in Immunology

05-May-20

Minyu Wang

Materials

10 PBMC from gastric patiens

Number of markers

32 markers

CD8+ T cells and FOXP3+CD4+ T cells as a significant prognostic marker for GC patient

High‐dimensional analyses reveal a distinct role of T‐cell subsets in the immune microenvironment of gastric cancer

Clinical & Translational Immunology

01-May-20

Manman Deng

Materials

57 adult patients and 11 normal controls, and xenografts models

Number of markers

9 markers

Efficacy of apatinib, targeting VEGFR2. patinib significantly inhibited growth and promoted apoptosis in AML cell lines in vitro. Similarly, apatinib showed cytotoxicity against primary AML cells but didn't affect normal BMMCs. apatinib suppressed AML growth and attenuated angiogenesis in xenograft models.

Apatinib exhibits cytotoxicity toward leukemia cells by targeting VEGFR2-mediated prosurvival signaling and angiogenesis

Experimental Cell Research

27-April-20

Pingping Hou

Materials

iKPC-3 primary tumors (n = 4) and HDAC5 escapers (n = 6) derived from subcutaneous allografts in nude
mice

Number of markers

20 markers

CyTOF analysis showed
a prominent switch in myeloid cell types from
neutrophil-rich CD45+CD11b+Ly6GhiLy6Clo cells in primary
tumors to macrophage-rich CD45+CD11b+F4/80+Ly6C− cells
in HDAC5 escapers

Tumor Microenvironment Remodeling
Enables Bypass of Oncogenic KRAS
Dependency in Pancreatic Cancer

Cancer Discovery

16-Apr-20

Joseph R. Podojil

Materials

Human tumor tissues

Number of markers

Not available

Mass cytometry shows localization of B7-H4 to a subset of CD68+ myeloid cells

Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma

Oncoimmunology

13-Apr-20

Yong-Hee Cho

Materials

9 NSCLC patients

Number of markers

30 markers

NK cell populations in the immune cells of PBMCs were prominently elevated in the immunotherapy responder group when compared with non-responders.

Natural Killer Cells as a Potential Biomarker for Predicting Immunotherapy Efficacy in Patients with Non-Small Cell Lung Cancer

Targeted Oncology

07-Apr-20

Claire L. Ihle

Materials

Prostate murine cancer model: MyC-CaP

Number of markers

26 markers

Conditional deletion of BMPR1a in myeloid cells (LysMCre) restricts tumor progression in a syngeneic mouse prostate cancer model. CyTOF profilig of myeloid subsets in the bone marrow, spleen and primary tumor shows that myeloid BMPR1a loss altered the differentiation and lineage capability of distinct populations

Loss of Myeloid BMPR1a Alters Differentiation and Reduces Mouse Prostate Cancer Growth

Frontiers in Oncology

06-Apr-20

Jennifer M. Rosenbluth

Materials

breast cancer organoids

Number of markers

38 markers

mass cytometry analysis of the multiple mammary epithelial cell types in organoids demonstrates that protein expression patterns of the tissue of origin can be preserved in culture

Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages

Nature Communications

29-Mar-20

David Kung-Chun Chiu

Materials

Hepa1-6 cells injected in mice

Number of markers

40 markers

CyTOF and high dimensional analysis reveals that anti-PD1 treatment up-regulates the expression of TIGIT in tumor-infiltrating CD8+ effector T cells

Hepatocellular Carcinoma Cells Upregulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice

Gastroenterology

23-Mar-20

Jason Ptacek

Materials

50 different cancer tissues

Number of markers

15 markers

Most samples showed infiltrating cytotoxic T cells and macrophages present amongst tumor cells.

Multiplexed ion beam imaging (MIBI) for characterization of the tumor microenvironment across tumor types

Laboratory Invetigation

23-Mar-20

Michael A. Postow

Materials

10 patients from each cohort, PBMC 3 different timepoints

Number of markers

38 markers

Comparison of radiotherapy + nivolumab + ipilimumab versus nivolumab + ipilimumab (no radiotherapy)

A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma

Clinical Cancer Research

23-Mar-20

Divya Mathur

Materials

multiple tumor cell lines, and in vivo in established subcutaneous and orthotopic human colorectal cancer xenograft tumors with adoptive transfer of human T cell

Number of markers

17 markers

T-cell engaging CD3 bispecific testing: PF-07062119 showed potent T-cell mediated in vitro activity and in vivo efficacy in multiple CRC human xenograft tumor models

A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers

Clinical Cancer Research

16-Mar-20

Won Jin Ho

Materials

42 samples: blood samples from two timepoints : baseline and 8weeks after antiPD1 therapy, 21 patients total

Number of markers

27 markers

Mass cytometry showed no significant effect of viral etiology on the tumor immune microenvironment in HCC, and viral status should not be used as a criterion to select patients for PD-1/PD-L1 therapy.

Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma (HCC)

Journal for Immunotherapy of Cancer

13-Mar-20

Sorah Yoon

Materials

Human pancreatic tissue

Number of markers

7 markers

Investigate the expression of seven markers related to the epithelial-to-mesenchymal transition in human pancreatic cancer tissue. High expression of α-SMA, vimentin, collagen I, and Ki-67 on grade I but not on grade III. HLA-DR was highly expressed on grade I/III but not on grade II.

Uncovering Differently Expressed Markers and Heterogeneity on Human Pancreatic Cancer

Translational Oncology

13-Mar-20

Ma, Y.

Materials

PDAC murine model KPC-Luc or mT4

Number of markers

33 markers

PD-L1 + OX-40 in PDAC rejects tumor in almost 100% of the mice mostly due to downregulation of Tregs. Tumor size was negatively associated with numbers of infiltrating CD4+ T cells, CD4+CD127+ T cells, and CD8+CD127+ T cells, and positively associated with numbers of CD4+PD-1+ T cells, CD4+CD25+ T cells, and CD8+PD-1+ T cells

Combination of PD1 inhibitor and OX40 agonist induces tumor rejection and immune memory in mouse models of pancreatic cancer

Gastroenterology

10-Mar-20

Pirozyan, M.R.

Materials

97 melanoma patients

Number of markers

39 markers

CD14+CD16− monocytes were higher and the major subset of NK cells (CD16hiCD56+) was significantly smaller in the primary resistance group compared with responders. T cell exhaustion markers were expressed in practically all patients and the major observation was an increase in CD39 on CD4 T cells during treatment.

Pretreatment innate cell populations and CD4 T cells in blood are associated with response to immune checkpoint blockade in melanoma patients

Frontiers in Immunology

01-Mar-20

Marwa Asem

Materials

3 mice/ genotype

Number of markers

20 markers

Peritoneal immune profiling by mass cytometry (Wnt5A knockout or control mice)

Host Wnt5a Potentiates Microenvironmental Regulation of Ovarian Cancer Metastasis

Cancer Research

27-Feb-20

Claire E. Gustafson

Materials

healthy controls (n = 15) and chemotherapy treated breast cancer patients (n = 15)

Number of markers

33 markers

How do cancer patients recover after chemotherapy: patients CD4+ T cells persisted for years and consisted of expansion of Th17-like CD4 memory populations with incomplete recovery of CD4+ naive T cells. CD8+ T cells fully recovered within a year

Immune cell repertoires in breast cancer patients after adjuvant chemotherapy

JCI Insight

19-Feb-20

Handan Xiang

Materials

Lung Squamous Cell Carcinoma tissue from 10 patients

Number of markers

17 markers

Lung squamous cell carcinoma patient–derived CAFs promoted recruitment of CCR2+ monocytes via CCL2, which could be reversed by CCR2 inhibition

Cancer-Associated Fibroblasts Promote Immunosuppression by Inducing ROS-Generating Monocytic MDSCs in Lung Squamous Cell Carcinoma

Cancer Immunology Research

18-Feb-20

Sophie A Dusoswa

Materials

glioblastoma glycocalyx as a tumor-intrinsic immune suppressor in an immunocompetent orthotopic glioma mouse model overexpressing truncated O-linked glycans

Number of markers

Not accessible

In an immunocompetent orthotopic glioma mouse model overexpressing truncated O-linked glycans (MGL ligands), high-dimensional mass cytometry revealed a wide heterogeneity of infiltrating myeloid cells with increased infiltration of PD-L1+ TAMs as well as distant alterations in the bone marrow

Glioblastomas exploit truncated O-linked glycans for local and distant immune modulation via the macrophage galactose-type lectin

PNAS

04-Feb-20

Weilun Fu

Materials

10 diffuse astrocytoma and 4 oliodendroglioma

Number of markers

33 markers

Increased percentages of PD-1+ CD8+ T cells, TIM-3+ CD4+ T cell subpopulations, Tregs and pro-tumor phenotype glioma-associated macrophages (GAMs) substantially contribute to the local immunosuppressive microenvironment in difuse astrocytoma (DA). DAs and oliodendroglioma (OGs) share similar compositions in terms of immune cells, while GAMs in DA exhibit more inhibitory characteristics than those in OG

High Dimensional Mass Cytometry Analysis Reveals Characteristics of the Immunosuppressive Microenvironment in Diffuse Astrocytomas

Frontiers in Oncology

31-Jan-20

Eri Sugiyama

Materials

Cannot access

Number of markers

Cannot access

EGFR-mutated lung adenocarcinomas have an immunosuppressive tumor microenvironment characterized by increased infiltration of regulatory T cells. The EGFR inhibitor erlotinib decreased CD4+ effector regulatory T cells infiltration in the TME and in combination with anti–PD-1 mAb showed better antitumor effects than treatment alone

Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer

Science Immunology

31-Jan-20

Giulia Parisi

Materials

In a B16-F10 murine melanoma model + confirmation in 5 patients receiving NKTR-214 in a phase 1 trial

Number of markers

22 markers

ACT with IL-2Rβγ increases the proliferation, homing and persistence of anti-tumor T cells compared to ACT with IL-2, resulting in superior antitumor activity.

Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist

Nature Communications

23-Jan-20

Shweta Joshi

Materials

in vivo syngeneic tumor models

Number of markers

Cannot access

MΦ Syk–PI3K axis drives polarization of immunosuppressive MΦs that establish an immunosuppressive tumor microenvironment in in vivo syngeneic tumor models.

Macrophage Syk–PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk–PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression

Molecular Cancer Therapeutics

20-Jan-20

Hartland W Jackson

Materials

352 patients

Number of markers

35 markers

single-cell phenotypes and their spatial context

The single-cell pathology landscape of breast cancer

Nature

20-Jan-20

Carlos R Figueiredo

Materials

4 primary uveal melanomas (for CyTOF)

Number of markers

28 markers

BAP1 loss is correlated with suppressive immune responses, including HLA‐DR, CD38, and CD74.

Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development

Journal of Pathology

19-Jan-20

Merav E. Shaul

Materials

64 advanced lung cancer, 35 early lung cancer, 13 chronic obstructive pulmonary disease, 15 Healthy

Number of markers

23 markers

Low Density Neutrophiles (LDN) were highly enriched in the low‐density fraction of advanced lung cancer patients but not in early stage patients, healthy individuals, or stable chronic obstructive pulmonary disease (COPD) patients. Elevated LDN related with poorer prognosis in late stage patients. CD66b+/CD10low/CXCR4+/PDL1inter subset almost exclusively found in advanced lung cancer patients

Circulating neutrophil subsets in advanced lung cancer patients exhibit unique immune signature and relate to prognosis

FASEB

15-Jan-20

Beth A Helmink

Materials

4 Responders (R) and 4 Non Responders (NR) for peripheral blood and n = 5 R and 3 NR for tumour

Number of markers

39 markers

Memory B cells were enriched in the tumours of responders

B cells and tertiary lymphoid structures promote immunotherapy response

Nature

07-Jan-20

Yaqing Zhang

Materials

5 pancreatic samples and mouse cancer model

Number of markers

Mouse: 16 markers/ Human: 16 markers

Tregs are a key source of TGFβ ligands. Treg depletion unleashed pathological CD4+ Tcell responses

Regulatory T cell depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis.

Cancer Discovery

04-Jan-20

Jiabo Di

Materials

18 patients with MSS CRC

Number of markers

30 markers

CD8+ CD28− immunosenescent T cells with impaired proliferation capacity dominate the T‐cell compartment. T‐cell profiles are similar between patients at early and late stages, indicating that the immunosuppressive microenvironment is formulated early during colorectal cancer (CRC) development

Phenotype molding of T cells in colorectal cancer by single‐cell analysis

IJC

19-Dec-19

Won Jin Ho

Materials

MC38 colon carcinoma cells subcutaneously into the right hind limb of C57BL/6 mice

Number of markers

3 panels: 20, 21, 24

Stumor of draining lymph node in anti-PD-1 therapy in mouse models: anti–PD-1 therapy enhances remodeling of both B and T cell compartments toward memory phenotypes.

Multipanel mass cytometry reveals anti–PD-1 therapy–mediated B and T cell compartment remodeling in tumor-draining lymph nodes

JCI Insight

  • Facebook
  • LinkedIn

©2021 by VisuaLyte |  info@visualyte.com |  Olley